|
Lopez Robles J, Carmona-Bayonas A, Jimenez-Fonseca P. Decoding risk: Caravaggio's insights into risk factors for anticoagulation in cancer-associated thrombosis. Eur J Intern Med. 2023 Jun;112:21-23. doi: 10.1016/j.ejim.2023.03.022. Epub 2023 Mar 28. No abstract available. PubMed PMID: 36990876.
AÑO: 2023; IF: 5.9
|
36990876
|
Carmona-Bayonas A, Rodriguez-Gonzalez A, Garcia-Garcia T, Velasco-Durantez V, Hernandez-San Gil R, Cruz-Castellanos P, Fernandez-Montes A, Castillo-Trujillo A, Ballester I, Rogado J, Calderon C, Jimenez-Fonseca P. Can Oncologists Prompt Patient Prognostic Awareness to Enhance Decision-Making? Data From the NEOetic Study. Oncologist. 2023 Nov 2;28(11):986-995. doi: 10.1093/oncolo/oyad100. PubMed PMID: 37185783; PubMed Central PMCID: PMC10628594.
AÑO: 2023; IF: 4.8
|
|
Mitjavila M, Jimenez-Fonseca P, Bello P, Pubul V, Percovich JC, Garcia-Burillo A, Hernando J, Arbizu J, Rodeno E, Estorch M, Llana B, Castellon M, Garcia-Canamaque L, Gajate P, Riesco MC, Miguel MB, Balaguer-Munoz D, Custodio A, Cano JM, Repetto A, Garcia-Alonso P, Muros MA, Vercher-Conejero JL, Carmona-Bayonas A. Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2486-2500. doi: 10.1007/s00259-023-06166-8. Epub 2023 Mar 6. PubMed PMID: 36877234; PubMed Central PMCID: PMC10250456.
AÑO: 2023; IF: 8.6
|
|
Lee EM, Jimenez-Fonseca P, Carmona-Bayonas A, Hernandez R, Cruz-Castellanos P, Obispo B, Antonanzas-Basa M, Palacin-Lois M, Castillo-Trujillo OA, Calderon C. Clinicians' and Advanced Cancer Patients' Estimates of Treatment Efficacy and Toxicity in Oncologic Treatment. Healthcare (Basel). 2023 Aug 7;11(15):2222. doi: 10.3390/healthcare11152222. PubMed PMID: 37570462; PubMed Central PMCID: PMC10419268.
AÑO: 2023; IF: 2.4
|
|
Capdevila J, Hernando J, Teule A, Lopez C, Garcia-Carbonero R, Benavent M, Custodio A, Garcia-Alvarez A, Cubillo A, Alonso V, Carmona-Bayonas A, Alonso-Gordoa T, Crespo G, Jimenez-Fonseca P, Blanco M, Viudez A, La Casta A, Sevilla I, Segura A, Llanos M, Landolfi S, Nuciforo P, Manzano JL. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. Nat Commun. 2023 May 23;14(1):2973. doi: 10.1038/s41467-023-38611-5. PubMed PMID: 37221181; PubMed Central PMCID: PMC10204675.
AÑO: 2023; IF: 14.7
|